The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.17
Ask: 0.20
Change: 0.01 (5.71%)
Spread: 0.03 (17.647%)
Open: 0.175
High: 0.00
Low: 0.00
Prev. Close: 0.175
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

20 Aug 2020 11:33

RNS Number : 7285W
Nuformix PLC
20 August 2020
 

Nuformix plc

("Nuformix" or the "Group")

 

 

Result of Annual General Meeting held on 20 August 2020

 

 

Cambridge, UK - 20 August 2020: Nuformix plc (LSE:NFX) announces that all resolutions proposed at its Annual General Meeting held today were duly passed on a poll, the results of which are set out below:

 

 

Votes For

% of Votes Cast

Votes Against

% of Votes Cast

Votes Withheld1

1

To receive the annual report and accounts for the year ended 31 March 2020

160,439,143

97.06

4,859,946

2.94

3,215,648

2

To approve the remuneration report contained within the Annual Report for the year ended 31 March 2020

160,409,517

97.05

4,871,780

2.95

3,233,440

3

To re-appoint Jo Holland as a director

160,421,351

97.06

4,859,946

2.94

3,233,440

4

To re-appoint Christopher Blackwell as a director

139,069,040

82.53

29,447,905

17.47

17,792

5

To appoint Karl Keegan as a director

139,057,206

82.52

29,459,739

17.48

17,792

6

To re-appoint Haysmacintyre as auditor of the Company

160,439,143

97.06

4,859,946

2.94

3,215,648

7

To authorise the directors to determine the remuneration of the auditor

160,421,351

97.05

4,877,738

2.95

3,215,648

8

To authorise the directors to allot shares

139,069,040

84.13

26,230,049

15.87

3,215,648

9

Authority to disapply pre-emption without restriction as to use (Special Resolution)

139,069,040

84.13

26,230,049

15.87

3,215,648

10

Authority to disapply pre-emption for acquisitions or specified capital investments (Special Resolution)

148,518,064

84.99

26,230,049

15.01

3,215,648

11

To authorise the Company to purchase its own shares (Special Resolution)

169,876,333

97.21

4,871,780

2.79

3,215,648

12

To authorise the Company to call a general meeting on not less than 14 clear days' notice (Special Resolution)

148,506,230

84.98

26,241,883

15.02

3,215,648

 

 

1 A vote withheld is not a vote under English law and is therefore not included in the calculation of votes for and against a resolution.

In accordance with Listing Rule 9.6.2, a copy of all resolutions passed as special business will shortly be available for inspection at the National Storage Mechanism document viewing facility at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

Enquiries:

 

Nuformix plc

Roger Jones, Company Secretary

Fleur Wood, Investor Relations

Email: fleur.wood@nuformix.com

 

 

+44 (0)1223 627222

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGBBLFLBVLXBBF
Date   Source Headline
15th Jan 202012:43 pmRNSAmendment to Notice
10th Jan 202011:45 amRNSIssue of Equity
8th Jan 20208:17 amRNSHolding(s) in Company
24th Dec 20197:00 amRNSHalf-year Report
25th Nov 20194:41 pmRNSSecond Price Monitoring Extn
25th Nov 20194:36 pmRNSPrice Monitoring Extension
25th Nov 20197:00 amRNSUpdate and Placing Announcement
28th Oct 20192:05 pmRNSSecond Price Monitoring Extn
28th Oct 20192:00 pmRNSPrice Monitoring Extension
28th Oct 20198:30 amRNSIssue of Equity
25th Oct 201911:11 amRNSStatement re. Share Price Movement
25th Oct 20199:05 amRNSSecond Price Monitoring Extn
25th Oct 20199:00 amRNSPrice Monitoring Extension
20th Sep 20192:05 pmRNSSecond Price Monitoring Extn
20th Sep 20192:00 pmRNSPrice Monitoring Extension
10th Sep 20194:49 pmRNSAGM Results
10th Sep 20197:00 amRNSDirectorate Change
9th Sep 20197:00 amRNSEbers Cannabinoid Collaboration Update
6th Sep 20197:30 amRNSAppointment of Dr Muhunthan Thillai
4th Sep 20197:30 amRNSHolding(s) in Company
1st Aug 20199:30 amRNSAnnual Financial Report
29th Jul 20197:00 amRNSHolding(s) in Company
18th Jul 20197:00 amRNSFinal Results
7th Jun 20197:00 amRNSHolding(s) in Company
6th Jun 20197:00 amRNSHolding(s) in Company
30th May 201911:05 amRNSSecond Price Monitoring Extn
30th May 201911:00 amRNSPrice Monitoring Extension
30th May 20197:01 amRNSPositive Results for NXP001 Clinical Trial
28th May 20197:00 amRNSHolding(s) in Company - Amendment
24th May 20197:30 amRNSHolding(s) in Company
24th May 20197:00 amRNSLoan Conversion
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHolding(s) in Company
15th May 20194:40 pmRNSSecond Price Monitoring Extn
15th May 20194:35 pmRNSPrice Monitoring Extension
15th May 20197:00 amRNSNuformix Achieves 2nd NXP001 Development Milestone
10th May 20199:00 amRNSPrice Monitoring Extension
8th May 20197:30 amRNSHolding(s) in Company
9th Apr 20197:00 amRNSStrategic Cannabinoid Agreement
5th Apr 20197:00 amRNSNotification Major Share Interests
22nd Mar 20197:00 amRNSNuformix Commences NXP001 Clinical Trial
27th Feb 20197:00 amRNSMHRA approval for NXP001
20th Feb 20196:16 pmRNSHolding(s) in Company
20th Dec 20187:00 amRNSUnaudited Half Year Results
3rd Dec 20187:00 amRNSReports Results from Novel IPF Pre-Clinical Trial
27th Nov 20187:00 amRNSExpansion of NXP001 Agreement & Milestone Payment
28th Sep 201810:09 amRNSDirector/PDMR Shareholding
28th Sep 20187:00 amRNSAdditional New NXP002 Patent Filing
19th Sep 20182:33 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.